Estrogen receptor degrader increases progression-free survival in advanced breast cancer patients

Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO 2016 Congress in Copenhagen

View article:
Estrogen receptor degrader increases progression-free survival in advanced breast cancer patients

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share